198226-63-0 Usage
General Description
2-Methyl-1-(naphthalen-2-yl)propan-2-amine, also known as methamphetamine, is a potent central nervous system stimulant that is commonly used as a recreational drug. It is a highly addictive substance and is classified as a Schedule II controlled substance in the United States. Methamphetamine increases the release of dopamine in the brain, leading to feelings of euphoria, increased energy, and a heightened sense of well-being. However, it also has numerous negative effects on the body, including increased heart rate and blood pressure, decreased appetite, and potential long-term damage to the brain. Chronic use of methamphetamine can also lead to addiction, paranoia, and other psychological issues. Overall, 2-Methyl-1-(naphthalen-2-yl)propan-2-amine has significant potential for abuse and can be highly dangerous to both physical and mental health.
Check Digit Verification of cas no
The CAS Registry Mumber 198226-63-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,9,8,2,2 and 6 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 198226-63:
(8*1)+(7*9)+(6*8)+(5*2)+(4*2)+(3*6)+(2*6)+(1*3)=170
170 % 10 = 0
So 198226-63-0 is a valid CAS Registry Number.
InChI:InChI=1/C14H17N/c1-14(2,15)10-11-7-8-12-5-3-4-6-13(12)9-11/h3-9H,10,15H2,1-2H3
198226-63-0Relevant articles and documents
CALCIUM RECEPTOR ANTAGONISTS
-
, (2008/06/13)
wherein R1 is optionally substituted aryl group or optionally substituted heteroaryl group; R2 is optionally substituted C1-6 alkyl group, C3-7 cycloalkyl group and the like; R3 is hydrogen atom, C1-6 alkyl group, hydroxyl group and the like; R4 is hydrogen atom, C1-6 alkyl group and the like; R5 and R6 are each C1-6 alkyl group and the like; R7 is optionally substituted aryl group or optionally substituted heteroaryl group; X1, X2 and X3 are each C1-6 alkylene group and the like; and X4 and X5 are each a single bond, methylene group and the like, a salt thereof, a solvate thereof or a prodrug thereof, and a pharmaceutical composition containing the compound, particularly a calcium receptor antagonist and a therapeutic agent for osteoporosis, are provided. The compound of the present invention is useful as a therapeutic drug of diseases accompanied by abnormal calcium homeostasis, or osteoporosis, hypoparathyreosis, osteosarcoma, periodontal disease, bone fracture, steoarthrosis, chronic rheumatoid arthritis, Paget's disease, humoral hypercalcemia, autosomal dominant hypocalcemia and the like. In addition, an intermediate for the compound is provided.
